With over 10 years in corporate pharmaceutical business development, strategy & operational leadership, Dr. Odumosu brings a unique combination of experiences from academic, public health and life science organizations. In his role as Ilera Healthcare’s first Chief Operating Officer, Dr Odumosu was a core part of the executive team in establishing and managing Ilera’s business operation’s post license award in 2017 through to profitability.

He served as Chief Scientific Officer/EVP Pharmaceutical Division for TerrAscend Corp. Prior to Ilera and Zelira, Dr. Odumosu played a critical role in Iroko Pharmaceutical’s post-clinical development of Zorvolex® Tivorbex® and Vivlodex® through FDA approvals and successful US market commercialization. He received a PhD in Biochemistry and a Master’s in Public Health-Epidemiology and Biostatistics from the Loma Linda University School of Medicine and School of Public Health in Loma Linda, California; and a BS in Biology from Calvin College in Grand Rapids, Michigan.

Dr. Odumosu is a World Bank Institute Certified public health professional with global healthcare translational/clinical/epidemiological research and data management experience.